IP Library › Granted Patent US 11,135,307
Granted Patent B2
US 11,135,307 · App. 15/819,650 · Granted Oct 5, 2021

Peptide-containing linkers for antibody-drug conjugates

Inventors: Aleksandr V. Yurkovetskiy (Littleton, MA); Natalya D. Bodyak (Boston, MA); Bingfan Du (Cambridge, MA); Dmitry R. Gumerov (Waltham, MA); Mariya Kozytska (Brookline, MA); Timothy B. Lowinger (Carlisle, MA); Cheri A. Stevenson (Haverhill, MA); Mao Yin (Needham, MA)
Assignee: Mersana Therapeutics, Inc.
A61K47/6889A61K38/07A61K47/65A61K47/6803A61K47/6849A61K47/6851A61K47/6855A61K47/6883A61K47/6885A61P35/00A61K47/549A61K47/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,135,307
App. No.
15/819,650
Granted
Oct 5, 2021
Kind
B2
Abstract

The present disclosure relates generally to antibody-drug conjugates comprising peptide-containing linkers and to methods of using these conjugates as therapeutics and/or diagnostics. Also disclosed herein are peptide-containing scaffolds useful to conjugate with a targeting moiety (e.g., an antibody), a drug, or both to produce the antibody-drug conjugates.

Claims (14)

1. A conjugate selected from the group consisting of:

wherein d 13 is 4 or 5; PBRM is a protein based recognition-molecule; and XMT-1535 comprises a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence SASQDIGNFLN (SEQ ID NO: 8); a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence YTSSLYS (SEQ ID NO: 9); a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence QQYSKLPLT (SEQ ID NO: 10); a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence GYTFTGYNIH (SEQ ID NO: 5); a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence AIYPGNGDTSYKQKFRG (SEQ ID NO: 6); and a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence GETARATFAY (SEQ ID NO: 7).

2. A conjugate of Formula (XXX):

wherein d 13 is 4 or 5; PBRM is a protein based recognition-molecule; and each R A is

wherein:

each occurrence of D is independently a therapeutic agent having a molecular weight≤about 5 kDa; and

each occurrence of L D is independently a divalent linker moiety connecting D to the peptide moiety and comprises at least one cleavable bond such that when the bond is broken, D is released in an active form for its intended therapeutic effect.

3. The conjugate of claim 2 , wherein each R A is

4. The conjugate of claim 2 , wherein each R A is

5. A pharmaceutical composition comprising a conjugate of claim 2 and a pharmaceutically acceptable carrier.

6. The conjugate of claim 2 , wherein each R A is

7. The conjugate of claim 2 , wherein each R A is

8. A conjugate being of Formula (XXX):

wherein d 13 is 4 or 5; PBRM is a protein based recognition-molecule; and each R A is

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2017
From: YURKOVETSKIY, ALEKSANDR V.; BODYAK, NATALYA D/; DU, BINGFAN; GUMEROV, DMITRY R.; KOZYTSKA, MARIYA; LOWINGER, TIMOTHY B.; STEVENSON, CHERI A.; YIN, MAO
To: MERSANA THERAPEUTICS, INC.
Reel/Frame 044354/0669 →
Continuity (3)
Provisional Application 62572010 · Oct 13, 2017
Provisional Application 62425895 · Nov 23, 2016
Related Publication 20180154018A1 · Jun 7, 2018